RadNet, Inc. (NASDAQ:RDNT) Holdings Increased by Whittier Trust Co.

Whittier Trust Co. boosted its holdings in RadNet, Inc. (NASDAQ:RDNT) by 5.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 197,921 shares of the medical research company’s stock after buying an additional 10,060 shares during the quarter. Whittier Trust Co. owned 0.27% of RadNet worth $13,732,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of RadNet by 8.1% during the first quarter. Vanguard Group Inc. now owns 4,600,539 shares of the medical research company’s stock worth $223,862,000 after acquiring an additional 345,822 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of RadNet by 11.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,131,849 shares of the medical research company’s stock valued at $78,539,000 after buying an additional 119,875 shares during the last quarter. Hood River Capital Management LLC grew its stake in shares of RadNet by 5.1% in the 2nd quarter. Hood River Capital Management LLC now owns 1,125,712 shares of the medical research company’s stock valued at $66,327,000 after buying an additional 54,583 shares in the last quarter. Global Alpha Capital Management Ltd. increased its holdings in RadNet by 16.2% in the first quarter. Global Alpha Capital Management Ltd. now owns 1,019,934 shares of the medical research company’s stock worth $49,630,000 after buying an additional 141,830 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in RadNet by 3.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 771,662 shares of the medical research company’s stock valued at $26,831,000 after acquiring an additional 27,311 shares in the last quarter. 77.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RDNT has been the subject of a number of recent analyst reports. Jefferies Financial Group upped their price target on shares of RadNet from $75.00 to $80.00 and gave the company a “buy” rating in a report on Thursday, September 19th. Truist Financial upped their target price on shares of RadNet from $70.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Barclays raised shares of RadNet from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $57.00 to $79.00 in a report on Friday, September 6th. Finally, Sidoti upgraded shares of RadNet to a “strong-buy” rating in a research report on Friday, October 4th. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, RadNet presently has an average rating of “Moderate Buy” and an average target price of $74.75.

RadNet Trading Down 1.4 %

RDNT traded down $0.95 during trading on Monday, reaching $67.21. 182,100 shares of the company’s stock were exchanged, compared to its average volume of 551,043. The firm has a fifty day moving average price of $66.20 and a two-hundred day moving average price of $59.93. RadNet, Inc. has a one year low of $25.11 and a one year high of $72.18. The stock has a market capitalization of $4.97 billion, a PE ratio of 227.20 and a beta of 1.74. The company has a current ratio of 2.12, a quick ratio of 2.12 and a debt-to-equity ratio of 0.92.

RadNet (NASDAQ:RDNT) last issued its quarterly earnings data on Wednesday, August 7th. The medical research company reported $0.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.01). RadNet had a return on equity of 4.30% and a net margin of 0.58%. The firm had revenue of $459.70 million during the quarter, compared to the consensus estimate of $438.53 million. During the same period in the previous year, the company posted $0.24 earnings per share. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. As a group, equities research analysts forecast that RadNet, Inc. will post 0.6 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Michael N. Murdock sold 15,000 shares of RadNet stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $62.78, for a total value of $941,700.00. Following the sale, the executive vice president now directly owns 48,144 shares in the company, valued at approximately $3,022,480.32. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.12% of the stock is owned by insiders.

RadNet Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.